NCT01498874View on ClinicalTrials.gov

Efficacy and Safety Study of Gevokizumab to Treat Moderate to Severe Acne Vulgaris

PHASE2CompletedINTERVENTIONAL

Enrollment

127

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

April 30, 2013

Study Completion Date

June 30, 2013

Conditions

Acne Vulgaris

Interventions

DRUG

Placebo

Sterile solution administered subcutaneously on Day 0, Day 28, and Day 56

DRUG

gevokizumab

Sterile solution administered subcutaneously on Day 0, Day 28, and Day 56

DRUG

gevokizumab

Sterile solution administered subcutaneously on Day 0, Day 28, and Day 56

Trial Locations (19)

Unknown

Hot Springs

Riverside

San Diego

Denver

New Haven

Bay City

Fridley

Las Vegas

Albuquerque

Charlotte

High Point

Raleigh

South Euclid

Portland

Arlington

Austin

Houston

Salt Lake City

Richmond

All Listed Sponsors

lead

XOMA (US) LLC

INDUSTRY

NCT01498874 - Efficacy and Safety Study of Gevokizumab to Treat Moderate to Severe Acne Vulgaris | Biotech Hunter | Biotech Hunter